Merck, Harvard forge research agreement

Merck and Harvard Medical School have signed an agreement to jointly advance research programs in two core areas--oncology and central nervous system disorders. Financial details were not disclosed. The pharma and university giants say the deal is unique because:

  • Merck is funding six HMS labs, enabling the advancement of a broad range of projects
  • Researchers from both sides will work closely together
  • HMS and Merck are located within walking distance of each other in Boston, which will further enable a close partnership.

Universities are playing an increasingly important role in drug development: A recent worldwide analysis of biotech patents found that universities and public research institutions play the leading role in drug discovery.

- see Harvard's release

Related Articles:
Universities, public institutes lead biotech revolution. Report
NIH program to create academic research consortium. Report

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.